The Multidisciplinary Association for Psychedelic Studies (MAPS)

MAPS is an American nonprofit organization working to raise awareness and understanding of psychedelic substance and was founded in 1986 by Rick Doblin.

It is their projection and opinion that MDMA shall receive FDA approval for treatment of PTSD in 2023.

MDMA is capable of inducing unique psychopharmacological effects, such as:

Decreased feelings of fear and defensiveness
Increased feelings of wellbeing
Increased sociability and extroversion
Increased interpersonal trust
An alert state of consciousness

MAPS is currently sponsoring MAPP2, the second of two Phase 3 trials to support FDA approval of this Breakthrough-designated therapy.

In (MAPS) first Phase 3 study, 88% of participants with severe PTSD experienced a clinically significant reduction in PTSD diagnostic scores two months after their third session of MDMA-assisted therapy, compared to 60% of placebo participants.

Additionally, 67% of participants in the MDMA group compared to 32% of participants in the placebo group no longer met the criteria for PTSD remission two months after the sessions.

source: (MAPS).